Profile data is unavailable for this security.
About the company
Reneo Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
- Revenue in USD (TTM)0.00
- Net income in USD-70.71m
- Incorporated2014
- Employees8.00
- LocationReneo Pharmaceuticals Inc18575 Jamboree Road, Suite 275-SIRVINE 92612United StatesUSA
- Phone+1 (858) 283-0280
- Fax+1 (302) 674-5266
- Websitehttps://reneopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantern Pharma Inc | 0.00 | -17.53m | 46.16m | 21.00 | -- | 1.29 | -- | -- | -1.62 | -1.62 | 0.00 | 3.32 | 0.00 | -- | -- | 0.00 | -36.82 | -28.83 | -39.63 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Marker Therapeutics Inc | 3.32m | -12.21m | 46.29m | 8.00 | -- | 3.92 | -- | 13.94 | -1.38 | -0.636 | 0.3751 | 1.32 | 0.158 | -- | 1.69 | 415,107.50 | -58.12 | -53.74 | -70.75 | -62.25 | -- | -- | -367.79 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.76m | 46.88m | 17.00 | -- | 2.27 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -2.42m | 47.26m | 7.00 | -- | -- | -- | -- | -0.0339 | -0.0339 | 0.00 | -0.042 | 0.00 | -- | -- | 0.00 | -97.97 | -- | -- | -- | -- | -- | -- | -- | -- | -25.68 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
| LAVA Therapeutics NV | 12.54m | -28.59m | 47.32m | 37.00 | -- | 0.934 | -- | 3.77 | -1.07 | -1.07 | 0.4668 | 1.93 | 0.107 | -- | 9.09 | 338,837.80 | -24.40 | -- | -28.91 | -- | 79.64 | -- | -228.02 | -- | -- | -- | 0.108 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 47.67m | 53.00 | -- | 1.59 | -- | 6.79 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -82.19m | 48.69m | 51.00 | -- | 0.5187 | -- | -- | -3.03 | -3.03 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -71.09 | -- | -80.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Arca Biopharma Inc | 0.00 | -6.00m | 50.34m | 4.00 | -- | 1.43 | -- | -- | -0.4155 | -0.4155 | 0.00 | 2.42 | 0.00 | -- | -- | 0.00 | -15.24 | -27.78 | -15.81 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 50.47m | 8.00 | -- | 0.6212 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -191.90m | 50.77m | 117.00 | -- | 0.2161 | -- | -- | -11.49 | -11.49 | 0.00 | 13.88 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Rallybio Corp | 0.00 | -76.28m | 53.06m | 43.00 | -- | 0.5429 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Ovid Therapeutics Inc | 473.53k | -50.68m | 53.33m | 40.00 | -- | 0.6797 | -- | 112.62 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Provectus Biopharmaceuticals Inc | 590.75k | -2.78m | 53.43m | 4.00 | -- | -- | -- | 90.44 | -0.0066 | -0.0066 | 0.0014 | -0.0178 | 0.4221 | -- | 1,358.05 | 147,687.50 | -198.50 | -276.33 | -- | -- | -- | -- | -470.31 | -1,667.76 | -- | -10.24 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| VolitionRX Ltd | 797.03k | -34.91m | 53.49m | 110.00 | -- | -- | -- | 67.11 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
Data as of Jul 03 2024. Currency figures normalised to Reneo Pharmaceuticals Inc's reporting currency: US Dollar USD
48.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 14 May 2024 | 3.69m | 11.05% |
| Tang Capital Management LLCas of 31 Mar 2024 | 3.00m | 8.97% |
| Highbridge Capital Management LLCas of 31 Mar 2024 | 2.74m | 8.19% |
| Octagon Capital Advisors LPas of 31 Mar 2024 | 2.25m | 6.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 947.68k | 2.84% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 909.64k | 2.72% |
| Aisling Capital Management LPas of 31 Mar 2024 | 886.08k | 2.65% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 751.73k | 2.25% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 593.30k | 1.78% |
| Acuitas Investments LLCas of 31 Mar 2024 | 404.05k | 1.21% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
